PALI ▲ +1.9% - Palisade Bio, Inc.
$PALI - Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
12-OCT-2026 08:05 AM ET
Share this post
More filings for $PALI
PALI - Palisade Bio, Inc. - SEC Filing Update (30-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 30, 2026PALI ▲ +2.5% - Palisade Bio, Inc.Oct 28, 2026PALI ▲ +0.7% - Palisade Bio, Inc.Sep 28, 2026PALI ▲ +0.6% - Palisade Bio, Inc.Sep 23, 2026PALI ▲ +3.6% - Palisade Bio, Inc.Sep 22, 2026PALI ▲ +3.8% - Palisade Bio, Inc.Sep 21, 2026
View full $PALI filing history →💬 Comments
Loading comments…
Leave a comment